April 25, 2023: BioPharma Reporter - FDA lifts 18-month clinical hold on MaaT Pharma's microbiome therapeutic

Previous PostApril 28, 2023: Microbiome Post - MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
Next PostApril 24, 2023 : Endpoints News - FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII

April 25, 2023: BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic